Affordable Access

deepdyve-link
Publisher Website

Review of 10 years of marketing experience with Chinese domestic inactivated hepatitis A vaccine Healive®.

Authors
  • Wu, Jun-Yu
  • Liu, Yan
  • Chen, Jiang-Ting
  • Xia, Ming
  • Zhang, Xiao-Mei
Type
Published Article
Journal
Human Vaccines & Immunotherapeutics
Publisher
Informa UK (Taylor & Francis)
Publication Date
Dec 01, 2012
Volume
8
Issue
12
Pages
1836–1844
Identifiers
DOI: 10.4161/hv.21909
PMID: 23032165
Source
Medline
Keywords
License
Unknown

Abstract

In 2002, the first Chinese domestic preservative-free inactivated hepatitis A vaccine, Healive®, was introduced in China. It is highly immunogenic, and provides lasting protection in healthy individuals and generates protective levels of antibodies in other at-risk individuals. Over 10 years since its first licensure, postmarketing surveillance data have confirmed the outstanding safety profile of the vaccine. Comparative clinical trials indicated that Healive® induce equal or similar immunogenicity with other currently available inactivated hepatitis A vaccines and are interchangeable for the course of HAV immunization in Chinese children. The vaccine is effective in curbing outbreaks of hepatitis A due to rapid seroconversion and the long incubation period of the disease. Additional issues surrounding the use of the vaccine are also reviewed.

Report this publication

Statistics

Seen <100 times